New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.

Détails

ID Serval
serval:BIB_D1A610DE5323
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Périodique
Neurosurgical Focus
Auteur(s)
Dehdashti A.R., Hegi M.E., Regli L., Pica A., Stupp R.
ISSN
1092-0684[electronic]
Statut éditorial
Publié
Date de publication
2006
Volume
20
Numéro
4
Pages
E6
Langue
anglais
Notes
Publication types: Journal Article ; Review
Résumé
Standard care for newly diagnosed glioblastoma multiforme (GBM) previously consisted of resection to the greatest extent feasible, followed by radiotherapy. The role of chemotherapy was controversial and its efficacy was marginal at best. Five years ago temozolomide (TMZ) was approved specifically for the treatment of recurrent malignant glioma. The role of TMZ chemotherapy administered alone or as an adjuvant therapy for newly diagnosed GBM has been evaluated in a large randomized trial whose results suggested a significant prolongation of survival following treatment. Findings of correlative molecular studies have indicated that methylguanine methyltransferase promoter methylation may be used as a predictive factor in selecting patients most likely to benefit from such treatment. In this short review the authors summarize the current role of TMZ chemotherapy in the management of GBM, with an emphasis on approved indications and practical aspects.
Mots-clé
Antineoplastic Agents, Alkylating, Brain Neoplasms, Clinical Trials as Topic, DNA Methylation, Dacarbazine, Glioblastoma, Humans, Methyltransferases, Neoplasm Recurrence, Local, Patient Selection, Treatment Outcome
Pubmed
Création de la notice
28/01/2008 8:39
Dernière modification de la notice
20/08/2019 15:51
Données d'usage